NYSE · Financial Statements

Teva Pharmaceutical Industries Limited (TEVA) Revenue, Earnings & Financial Statements

$42.62 NYSE: TEVA Market Cap $49.73B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Teva Pharmaceutical Industries Limited most recently reported annual revenue of $17.3B, net profit of $1.4B. Revenue grew at an average annual rate of 0.7% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Teva Pharmaceutical Industries Limited: Revenue fell from $21.9B in 2016 to $17.3B in 2025, a change of -21.2% over 9 years; net profit was positive in 3 of 10 reported years; operating margin moved from 9.8% to 12.5%, a shift of +2.7 percentage points; the most recent year shows net profit of $1.4B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$21.9B$22.4B$18.9B$16.9B$16.7B$15.9B$14.9B$15.8B$16.5B$17.3B
Operating Expenses$19.7B$39.9B$20.5B$17.3B$20.2B$14.2B$17.1B$15.4B$16.8B$15.1B
Operating Profit$2.2B−$17.5B−$1.6B−$443.0M−$3.6B$1.7B−$2.2B$433.0M−$303.0M$2.2B
Operating Margin9.8%-78.1%-8.7%-2.6%-21.4%10.8%-14.7%2.7%-1.8%12.5%
Other Income−$1.3B−$895.0M−$959.0M−$280.0M−$359.0M−$1.0B−$945.0M−$1.1B−$980.0M−$919.0M
Interest$1.3B$895.0M$881.0M$957.0M$755.0M$891.0M$930.0M$1.0B$941.0M$916.0M
Depreciation$1.5B$2.1B$1.8B$1.7B$1.6B$1.3B$1.3B$1.2B$1.1B$1.0B
Profit Before Tax$824.0M−$18.4B−$2.6B−$723.0M−$3.9B$667.0M−$3.1B−$622.0M−$1.3B$1.2B
Tax rate (%)63.2%10.5%7.5%-38.5%-4.3%31.6%20.5%1.1%-52.7%-14.5%
Net Profit$329.0M−$16.3B−$2.1B−$999.0M−$4.0B$417.0M−$2.4B−$559.0M−$1.6B$1.4B
EPS$0.07−$16.01−$2.11−$0.92−$3.64$0.38−$2.20−$0.50−$1.45$1.20

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$4.5B$3.8B$4.2B$4.3B$4.2B$3.9B$4.2B$4.5B$4.7B$4.0B$4.1B$4.4B
Operating Expenses$3.7B$4.0B$4.2B$4.4B$4.3B$3.4B$3.7B$3.6B$4.4B$3.3B$4.0B$3.7B
Operating Profit$756.0M−$218.0M−$5.0M−$51.0M−$29.0M$519.0M$455.0M$882.0M$300.0M$652.0M$149.0M$714.0M
Operating Margin17.0%-5.7%-0.1%-1.2%-0.7%13.3%10.9%19.7%6.4%16.4%3.6%16.3%
Interest$260.0M$250.0M$241.0M$272.0M$763.0M$225.0M$203.0M$209.0M$292.0M$201.0M$200.0M$0
Profit Before Tax$508.0M−$471.0M−$244.0M−$321.0M−$247.0M$294.0M$204.0M$648.0M$91.0M$436.0M−$455.0M$300.0M
Tax rate (%)8.1%11.0%-258.2%-21.5%-11.3%25.2%-38.2%33.0%-428.6%15.4%-26.6%22.0%
Net Profit$463.0M−$139.0M−$846.0M−$437.0M−$217.0M$214.0M$282.0M$433.0M$480.0M$369.0M−$576.0M$233.0M
EPS$0.41−$0.13−$0.74−$0.39−$0.19$0.18$0.24$0.37$0.41$0.31−$0.49$0.20

Over the 10 years reported for Teva Pharmaceutical Industries Limited, borrowings decreased from $35.8B in 2016 to $17.4B in 2025, cash stood at $3.6B in the latest year, shareholders' equity was $58.0M, current assets covered current liabilities 1.04 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$92.9B$70.6B$60.7B$57.5B$50.6B$47.7B$44.0B$43.5B$39.3B$40.7B
Current Assets$17.0B$15.4B$13.8B$13.5B$13.0B$12.6B$12.1B$12.5B$12.6B$13.9B
Cash$988.0M$963.0M$1.8B$2.0B$2.2B$2.2B$2.8B$3.2B$3.3B$3.6B
Inventory$5.0B$4.9B$4.7B$4.4B$4.4B$3.8B$3.8B$4.0B$3.0B$3.2B
Receivables$7.5B$7.1B$5.8B$5.7B$4.6B$4.5B$3.7B$3.4B$3.1B$3.7B
Fixed Assets$8.1B$7.7B$6.9B$7.0B$6.9B$6.5B$6.2B$6.1B$4.9B$4.4B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$88.0M$25.0M$58.0M$0$0$0$0$8.0M$0$0
Other Assets$44.4B$28.4B$24.9B$24.8B$20.6B$20.0B$17.6B$17.2B$15.1B$16.0B
Total Liabilities$57.9B$51.9B$44.9B$42.4B$39.6B$36.4B$35.4B$35.4B$33.6B$32.8B
Current Liabilities$18.5B$17.9B$14.3B$13.7B$13.2B$11.0B$11.5B$12.2B$12.8B$13.5B
Borrowings$35.8B$32.5B$28.9B$27.3B$26.4B$23.5B$21.6B$20.2B$18.1B$17.4B
Other Liabilities$22.1B$19.4B$16.0B$15.1B$13.2B$13.0B$13.9B$15.2B$15.5B$15.5B
Equity$54.0M$54.0M$56.0M$56.0M$57.0M$57.0M$57.0M$57.0M$58.0M$58.0M
Reserves$33.3B$17.4B$14.7B$14.0B$10.0B$10.3B$7.8B$7.5B$5.4B$7.9B

For Teva Pharmaceutical Industries Limited, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $1.1B; free cash flow was positive in 10 of 10 years; financing activities used $337.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$5.2B$3.5B$2.4B$538.0M$1.2B$798.0M$1.6B$1.4B$1.2B$1.6B
Investing Cash Flow−$34.6B$4.8B$1.2B$311.0M$285.0M$961.0M$108.0M$442.0M$294.0M$236.0M
Financing Cash Flow−$134.0M−$112.0M−$57.0M$1.7B−$5.0M−$6.0M−$118.0M−$212.0M−$150.0M−$337.0M
Net Cash Flow−$6.0B−$25.0M$819.0M$734.0M$202.0M$21.0M$636.0M$393.0M$73.0M$256.0M
Free Cash Flow$4.3B$2.6B$1.8B$419.0M$638.0M$236.0M$1.0B$842.0M$749.0M$1.1B

Valuation & Return Ratios

MetricValue
PEG Ratio-3.32
EV / EBITDA30.78
FCF Yield2.48%
Quick Ratio0.74
Interest Coverage2.62
Return 1Y70.48%
Return 3Y363.20%
Return 5Y366.30%

Teva Pharmaceutical Industries Limited (TEVA) financials — frequently asked questions

What is Teva Pharmaceutical Industries Limited's annual revenue?

Teva Pharmaceutical Industries Limited (TEVA) reported annual revenue of $17.3B in its most recent fiscal year.

What is Teva Pharmaceutical Industries Limited's net profit?

Teva Pharmaceutical Industries Limited (TEVA) reported net profit of $1.4B in its most recent fiscal year.

What is TEVA EV/EBITDA?

Teva Pharmaceutical Industries Limited's enterprise value to EBITDA (EV/EBITDA) ratio is 30.78.

Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks

ZTS revenue $9.5BVTRS revenue $14.3BELAN revenue $4.7BRDY revenue $353.5BALKS revenue $1.5BAMRX revenue $3.0BLNTH revenue $1.5BSUPN revenue $719.0MBHC revenue $10.3BRGC financialsAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
TEVA Overview TEVA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.